Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in early breast cancer patients

por Farolfi, Alberto, Silimbani, Paolo, Gallegati, Davide, Petracci, Elisabetta, Schirone, Alessio, Altini, Mattia, Masini, Carla
Publicado 2017

High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy

por Lupini, Laura, Moretti, Anna, Bassi, Cristian, Schirone, Alessio, Pedriali, Massimo, Querzoli, Patrizia, Roncarati, Roberta, Frassoldati, Antonio, Negrini, Massimo
Publicado 2018

Cell-free DNA detected by “liquid biopsy” as a potential prognostic biomarker in early breast cancer

por Maltoni, Roberta, Casadio, Valentina, Ravaioli, Sara, Foca, Flavia, Tumedei, Maria Maddalena, Salvi, Samanta, Martignano, Filippo, Calistri, Daniele, Rocca, Andrea, Schirone, Alessio, Amadori, Dino, Bravaccini, Sara
Publicado 2017

The Value of Semiquantitative Parameters Derived from (18)F-FDG PET/CT for Predicting Response to Neoadjuvant Chemotherapy in a Cohort of Patients with Different Molecular Subtypes...

por Urso, Luca, Evangelista, Laura, Alongi, Pierpaolo, Quartuccio, Natale, Cittanti, Corrado, Rambaldi, Ilaria, Ortolan, Naima, Borgia, Francesca, Nieri, Alberto, Uccelli, Licia, Schirone, Alessio, Panareo, Stefano, Arnone, Gaspare, Bartolomei, Mirco
Publicado 2022

Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer

por Rocca, Andrea, Cecconetto, Lorenzo, Passardi, Alessandro, Melegari, Elisabetta, Andreis, Daniele, Monti, Manuela, Maltoni, Roberta, Sarti, Samanta, Pietri, Elisabetta, Schirone, Alessio, Fabbri, Francesco, Donati, Caterina, Nanni, Oriana, Fedeli, Anna, Faedi, Marina, Amadori, Dino
Publicado 2017

Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II...

por Caputo, Roberta, Cazzaniga, Marina Elena, Sbrana, Andrea, Torrisi, Rosalba, Paris, Ida, Giordano, Monica, Montesarchio, Vincenzo, Guarneri, Valentina, Amaducci, Laura, Bilancia, Domenico, Cilenti, Giuseppina, Fabi, Alessandra, Collovà, Elena, Schirone, Alessio, Bonizzoni, Erminio, Celio, Luigi, De Placido, Sabino, De Laurentiis, Michelino
Publicado 2020

Phase II Study of Dehydroepiandrosterone in Androgen Receptor‐Positive Metastatic Breast Cancer

por Pietri, Elisabetta, Massa, Ilaria, Bravaccini, Sara, Ravaioli, Sara, Tumedei, Maria Maddalena, Petracci, Elisabetta, Donati, Caterina, Schirone, Alessio, Piacentini, Federico, Gianni, Lorenzo, Nicolini, Mario, Campadelli, Enrico, Gennari, Alessandra, Saba, Alessandro, Campi, Beatrice, Valmorri, Linda, Andreis, Daniele, Fabbri, Francesco, Amadori, Dino, Rocca, Andrea
Publicado 2018

Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial

por Conte, PierFranco, Bisagni, Giancarlo, Piacentini, Federico, Sarti, Samanta, Minichillo, Santino, Anselmi, Elisa, Aieta, Michele, Gebbia, Vittorio, Schirone, Alessio, Musolino, Antonino, Garrone, Ornella, Beano, Alessandra, Rimanti, Anita, Giotta, Francesco, Turletti, Anna, Miglietta, Federica, Dieci, Maria Vittoria, Vicini, Roberto, Balduzzi, Sara, D'Amico, Robert, Guarneri, Valentina
Publicado 2023

Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study

por Cazzaniga, Marina, Verusio, Claudio, Ciccarese, Mariangela, Fumagalli, Alberto, Sartori, Donata, Valerio, Maria Rosaria, Airoldi, Mario, Moretti, Gabriella, Ficorella, Corrado, Arcangeli, Valentina, Diodati, Lucrezia, Zambelli, Alberto, Febbraro, Antonio, Generali, Daniele, Pistelli, Mirco, Garrone, Ornella, Musolino, Antonino, Vici, Patrizia, Maur, Michela, Mentuccia, Lucia, La Verde, Nicla, Bianchi, Giulia, Artale, Salvatore, Blasi, Livio, Piezzo, Michela, Atzori, Francesco, Turletti, Anna, Benedetto, Chiara, Cursano, Maria Concetta, Fabi, Alessandra, Gebbia, Vittorio, Schirone, Alessio, Palumbo, Raffaella, Ferzi, Antonella, Frassoldati, Antonio, Scavelli, Claudio, Clivio, Luca, Torri, Valter
Publicado 2018

Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study

por Cazzaniga, Marina, Verusio, Claudio, Ciccarese, Mariangela, Fumagalli, Alberto, Sartori, Donata, Valerio, Maria Rosaria, Airoldi, Mario, Moretti, Gabriella, Ficorella, Corrado, Arcangeli, Valentina, Diodati, Lucrezia, Zambelli, Alberto, Febbraro, Antonio, Generali, Daniele, Pistelli, Mirco, Garrone, Ornella, Musolino, Antonino, Vici, Patrizia, Maur, Michela, Mentuccia, Lucia, La Verde, Nicla, Bianchi, Giulia, Artale, Salvatore, Blasi, Livio, Piezzo, Matilde, Atzori, Francesco, Turletti, Anna, Benedetto, Chiara, Cursano, Maria Concetta, Fabi, Alessandra, Gebbia, Vittorio, Schirone, Alessio, Palumbo, Raffaella, Ferzi, Antonella, Frassoldati, Antonio, Scavelli, Claudio, Clivio, Luca, Torri on behalf of The EVA Study Group, Valter
Publicado 2018